Monocarboxylate Transporter 8 Deficiency
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Egetis TherapeuticsSweden - Stockholm
2 programsTiratricolN/A1 trial
TiratricolPHASE_31 trial
Active Trials
NCT05911399Available
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
Egetis TherapeuticsTiratricol
Clinical Trials (2)
Total enrollment: 20 patients across 2 trials
Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)
Start: Jul 2023Est. completion: Sep 202520 patients
Phase 3Completed
Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency
N/AAvailable
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.